SCHEMBL596560

SCHEMBL596560

O=C1NCCNC1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRCP P42785 1/20 0.44
GAA P10253 2/20 0.43
GLA P06280 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GID4 Q8IVV7 3/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
KDM1A O60341 1/20 0.39
RAB9A P51151 1/20 0.39
MAP4K1 Q92918 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
GFER P55789 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26986647 1.00 PRCP (0.44) PRCPGAAGLAKDM4EALDH1A1
Tert-Butyl Formate SCHEMBL27849833 0.83 GLA (0.39) PRCPGAAGLAKDM4EALDH1A1
SCHEMBL27586954 0.82 MAP4K1 (0.42) GLAALDH1A1MAP4K1KMT2A
SCHEMBL20304287 0.81 DDB1 (0.40) PRCPGAAKDM4EALDH1A1DDB1
SCHEMBL9786155 0.80 TDP1 (0.50) PRCPGAAKDM4EALDH1A1KDM1A
SCHEMBL380027 0.80 TDP1 (0.50) PRCPGAAKDM4EALDH1A1KDM1A
SCHEMBL1673497 0.80 SLC6A3 (0.47) PRCPALDH1A1KDM1AMAP4K1
SCHEMBL5586396 0.80 SMN1; SMN2 (0.47) PRCPALDH1A1GID4KDM1ARAB9A
SCHEMBL17055320 0.80 SMN1; SMN2 (0.42) GAAKDM1ARAB9AMAP4K1MAPT
SCHEMBL31049590 0.80 MAP4K1 (0.41) GLAALDH1A1MAP4K1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103588715-A Synthetic method for 1-methyl-3-phenylpiperazine TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD 2014-02-19 CN claimed
US-20250353852-A1 COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE KINETA INC (US) 2025-11-20 US disclosed
EP-4444316-A1 COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2024009283-A1 AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-01-11 WO disclosed
WO-2023137634-A1 TRICYCLIC COMPOUND, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION AND USE 上海奕拓医药科技有限责任公司 2023-07-27 WO disclosed
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed
WO-2023107557-A1 COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107557-A1 COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE Kineta, Inc. (US) 2023-06-15 WO disclosed
CN-107174584-B Application of piperazine structure-containing compound in preparation of LSD1 inhibitor 福建金乐医药科技有限公司 2020-09-01 CN disclosed
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-07-07 US disclosed
WO-2002038552-A1 A NOVEL METHOD FOR THE PREPARATION OF PIPERAZINE AND ITS DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) 2002-05-16 WO disclosed
WO-2001025219-A2 PIPERAZINE COMPOUNDS GLAXO GROUP LIMITED (GB) 2001-04-12 WO disclosed
US-6051572-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME LTD. (GB) 2000-04-18 US disclosed
WO-1997016445-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-05-09 WO disclosed
US-5326760-A Aminobutanoic acid compounds having metalloprotease inhibiting properties GLAXO, INC. (US) 1994-07-05 US disclosed
WO-1994000119-A1 AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES GLAXO INC. (US) 1994-01-06 WO disclosed
EP-0300074-A1 Processes and intermediates useful in the preparation of Cis 1,3,4,6,7 llb-Hexa-hydro-7-aryl-2H-pyrazino[2,1-a]isoquinolines PENNWALT CORPORATION (US) 1989-01-25 EP disclosed
US-4772705-A Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines PENNWALT CORPORATION (US) 1988-09-20 US disclosed
US-4012389-A ANTICOAGULANTS DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) 1977-03-15 US disclosed
US-3935214-A ANTICOAGULANT DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353852-A1 COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE PIKFYVE, TARDBP, TDP1 PRCP 1287/4885GAA 1263/4885GLA 3037/4885
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB PRCP 726/4885GAA 2081/4885GLA 2986/4885
US-10703746-B2 Mutant IDH1 inhibitors useful for treating cancer IDH1, IDH3B, IDH3A PRCP 1576/4885GAA 141/4885GLA 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.